AGLE-102 is under clinical development by Aegle Therapeutics and currently in Phase II for Epidermolysis Bullosa. According to GlobalData, Phase II drugs for Epidermolysis Bullosa have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AGLE-102’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AGLE-102 overview
AGLE-102 (AG-110) is under development for the treatment of dystrophic epidermolysis bullosa, burns and graft versus host disease (GVHD). The therapeutic candidate constitutes microvesicles secreted by stem cells. It is developed based on Aegle’s microvesicle isolation method. It is administered through topical route.
Aegle Therapeutics overview
Aegle Therapeutics, a biotechnology company that focuses on isolating extracellular vesicles secreted by mesenchymal stem cells to treat severe dermatological conditions. The company is headquartered in Woburn, Massachusetts, the US.
For a complete picture of AGLE-102’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
